Athira Pharma (ATHA)
ATHA
Neuroscience
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer's disease. — Front Neurol 2026 PMID 42643714
- Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world. — Alzheimers Dement 2026 Jul PMID 42516031
- Quality of life and productivity among esketamine responders in a real-world study in Australia and New Zealand. — J Psychiatr Res 2026 Oct PMID 42501650
- Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. — EBioMedicine 2026 Aug PMID 42468111
- Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers. — EBioMedicine 2026 Jul PMID 42302428
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Athira Pharma.
Full ATHA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.